Author

Priscilla S. Briquez

University of FreiburgORCID 0000-0002-4680-9636Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

Aishwarya Saxena· 1 shared Carla AbrahamianiD· 1 shared Chiara Kling· 1 shared Christian GraesseriD· 1 shared Fuxin Zhou· 1 shared Hendrik B. SageriD· 1 shared Heribert SchunkertiD· 1 shared Holger SpiegeliD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aishwarya Saxena

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Antibody-mediated inhibition of ADAMTS-7 reduces experimental atherosclerosis

M. Amin Sharifi, Johannes Riechel, Michael J. Winkler, Tan An Dang, Christian Graesser, Philipp Müller, Carla Abrahamian, Nikita Panyam, Priscilla S. Briquez, Holger Spiegel, Hendrik B. Sager, Nicole P. G. Raven, Heribert Schunkert, Thorsten Kessler

This study develops a monoclonal antibody against ADAMTS-7 that reduces atherosclerosis in mice without affecting lipid levels or causing toxicity.

bioRxiv · Aug 19, 2026 · PreprintPhysiology

Membrane localisation and checkpoint blockade enhance xenoantigen delivery to redirect pre-existing immunity against tumours

Sylvie Hauert, Fuxin Zhou, Justas Šidiškis, Aishwarya Saxena, Zoe Goldberger, Kevin Chang, Chiara Kling, Natalie Köhler, Stefan Fichtner‐Feigl, Jeffrey A. Hubbell, Huda Jumaa, Priscilla S. Briquez

This study shows that membrane-localized xenoantigens enhance CD4+ T cell responses and improve anti-PD-1 therapy efficacy in pre-immunized mice, using OVA and VZV gE antigens.

bioRxiv · Mar 3, 2026 · PreprintCancer Biology